Aura BiosciencesAURA +14.92%35 Quick Ratio is 7.09 as of Mar. 2026, which is 50% below its 10-year median of 14.22. GuruFocus rates AURA with a GF Score™ of 35/100. The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Aura Biosciences ranks better than 70.02% on this metric.
Aura Biosciences has a quick ratio of 7.09. It generally indicates good short-term financial strength.
The historical rank and industry rank for Aura Biosciences's Quick Ratio or its related term are showing as below:
AURA'
s Quick Ratio Range Over the Past 10 Years
Min: 5.42 Med: 14.22 Max: 27.9
Current: 7.09
During the past 7 years, Aura Biosciences's highest Quick Ratio was 27.90. The lowest was 5.42. And the median was 14.22.
AURA's Quick Ratio is ranked better than 70.02% of 1411
companies
in the Biotechnology industry
Industry Median: 3.6
vs AURA: 7.09
Aura Biosciences (NAS:AURA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Aura Biosciences Quick Ratio Related Terms
Aura Biosciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for Aura Biosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aura Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aura Biosciences Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aura Biosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Aura Biosciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Aura Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aura Biosciences (AURA) has a Quick Ratio of 7.09 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aura Biosciences and its competitors. This is 50% below median its historical median of 14.22. Over the past decade, Aura Biosciences' Quick Ratio has ranged from 5.42 to 27.90. According to the industry distribution chart, Aura Biosciences ranks #423 out of 1411 companies in the Biotechnology industry, placing it in the top 30%.
Is Aura Biosciences' Quick Ratio too high?
Aura Biosciences' current Quick Ratio of 7.09 is 50% below median its 10-year median of 14.22. Over the past 10 years, this metric has ranged from a low of 5.42 to a high of 27.90. The Biotechnology industry median Quick Ratio is 3.60. Aura Biosciences' value of 7.09 is 96.9% above this industry median. Based on the distribution chart, Aura Biosciences ranks #423 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aura Biosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Aura Biosciences' Quick Ratio compare to NVCT and CADL?
According to the Biotechnology industry distribution chart, Aura Biosciences ranks #423 out of 1411 companies for Quick Ratio. This puts Aura Biosciences in the upper half of its industry. The industry median Quick Ratio is 3.60. Aura Biosciences' value of 7.09 is 96.9% above this benchmark. Historically, Aura Biosciences' own Quick Ratio has ranged from 5.42 to 27.90 over the past decade. While the company's 10-year median is 14.22 vs. the industry median of 3.60, Aura Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aura Biosciences's current Quick Ratio of 7.09 is 96.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aura Biosciences and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aura Biosciences's current Quick Ratio is 7.09, which is 50% below median its own 10-year median of 14.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aura Biosciences stock overvalued right now?
Aura Biosciences (AURA) has a current Quick Ratio of 7.09. The current Quick Ratio is 7.09, which is 50% below median its 10-year median of 14.22 and 96.9% above the Biotechnology industry median of 3.60. Aura Biosciences' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Aura Biosciences (AURA), the current Quick Ratio is 7.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
35GF Score
Get the complete analysis for AURA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURA has been successfully added to your 
